(Q28369617)

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

The molecular biology of the hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Use of digoxigenin-labelled probes for the quantitation of HBV-DNA in antiviral drug evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Synthesis and anti-hepatitis B virus activity of 9-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl) purine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Unique inhibitory effect of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil 5'-triphosphate on Epstein-Barr virus and human DNA polymerases

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Phosphorylation of 9-(2-phosphonomethoxyethyl)adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP(dAMP) kinase from L1210 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Lamivudine therapy of WHV-infected woodchucks.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Viral dynamics of HIV: implications for drug development and therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Robustaflavone, a potential non-nucleoside anti-hepatitis B agent

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021

Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900060-6

7 January 2021